Exciting Advances in AVIM Therapy for Blood Pressure Management
Orchestra BioMed Innovates with AVIM Therapy Data
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) has shared significant clinical data regarding their atrioventricular interval modulation (AVIM) therapy at a recent conference. These findings indicate that patients experiencing uncontrolled hypertension can benefit from sustained blood pressure reductions over extended periods. The therapy demonstrated reversibility without causing rebound hypertension when deactivated and can be reactivated effectively after a washout period.
Long-Term Effectiveness of AVIM Therapy
During the HRX Live 2025 Meeting, the company showcased results revealing that AVIM therapy leads to long-term decreases in blood pressure, which can be maintained for years post-activation. This therapy is particularly designed for individuals requiring a pacemaker, targeting over 750,000 patients annually who contend with high blood pressure.
Data Highlights from the Presentation
- Sustained Blood Pressure Reduction: A cohort from the MODERATO II trial exhibited significant 24-hour ambulatory systolic blood pressure (aSBP) reductions averaging 8.9 mmHg over 3.6 years (p<0.001).
- Reversible Treatment Effects: After a seven-day washout period, patients returned to the baseline hypertension level, indicating that no rebound hypertension was observed.
- Immediate Effectiveness on Reactivation: Once therapy is resumed, aSBP was significantly reduced to 124.4 mmHg within a day (p<0.002).
- Consistency of Effects: The therapeutic effects remained comparable during different intervals of assessments, reinforcing the reproducibility of the treatment.
The Role of Dr. Avi Fischer
Dr. Avi Fischer, Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed, emphasized the importance of these findings in addressing hypertension, particularly for patients whose conditions are resistant despite traditional medications. His presentation aligned with the peer-reviewed publication of AVIM therapy results, reinforcing the evidence of a robust safety profile and promising outcomes.
Implications for Patients
The sustainability, reversibility, and reproducibility of blood pressure reductions underscore the potential of AVIM therapy to manage hypertension effectively. This brings hope to millions facing cardiovascular risks.
About AVIM Therapy
AVIM therapy, also known as BackBeat Cardiac Neuromodulation Therapy (CNT™), is an investigational treatment aimed at significantly lowering blood pressure in patients who may require pacemaker intervention. Initial studies, such as the MODERATO II trial, have shown promising results with net reductions in both ambulatory and office systolic blood pressure, alongside improvements in cardiac function.
Strategic Collaborations and Future Developments
Orchestra BioMed's collaboration with Medtronic aims to further develop and commercialize AVIM therapy. Additionally, the company is involved in advancing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for atherosclerotic artery disease treatment. The broad implications of these therapies could save countless lives, given the global prevalence of hypertension and related conditions.
Frequently Asked Questions
What is AVIM therapy?
AVIM therapy is a medical treatment designed to lower blood pressure in patients, particularly those requiring pacemakers. It involves atrioventricular interval modulation to achieve sustained reductions in blood pressure.
How effective is AVIM therapy?
Clinical data show that AVIM therapy can achieve lasting reductions in blood pressure, with studies indicating a decrease of around 8.9 mmHg sustained over several years with no rebound hypertension upon treatment discontinuation.
Who can benefit from AVIM therapy?
Patients with uncontrolled hypertension, particularly those indicated for pacemaker treatments, stand to gain significantly from AVIM therapy, which targets the underlying causes of high blood pressure.
What are the future plans for Orchestra BioMed?
Orchestra BioMed intends to continue advancing AVIM therapy through strategic partnerships and collaborations, as well as furthering research and clinical studies to ensure its widespread availability and effectiveness in managing hypertension.
How can I learn more about Orchestra BioMed?
For more information about Orchestra BioMed and their innovative therapies, you can visit their official website or follow them on their social media platforms for updates and advancements in their projects.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.